X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TauRx's lead product candidate TRx0237 (hydromethylthionine), a tau protein inhibitor. Currently, it is being evaluated in the Phase III clinical trial studies for the treatment of Alzheimer's disease.
Lead Product(s): Hydromethylthionine
Therapeutic Area: Neurology Product Name: TRx0237
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
TRx0237 is a small molecule drug being tested for its ability to inhibit aggregation of tau, a protein that forms neurofibrillary tangles in the brains of people with Alzheimer's and other neurodegenerative diseases.
Lead Product(s): Hydromethylthionine
Therapeutic Area: Neurology Product Name: TRx0237
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
HMTM or TRx0237 is an oral tau aggregation inhibitor, targeting this underlying pathology. TauRx’s HMTM has the potential to become the first disease-modifying therapies (DMT) targeting tau to be approved for AD.
Lead Product(s): Hydromethylthionine
Therapeutic Area: Neurology Product Name: TRx0237
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing November 14, 2022
Details:
For people with early Alzheimer’s (MCI), HMTM, a potent inhibitor of Tau aggregation treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals.
Lead Product(s): Hydromethylthionine
Therapeutic Area: Neurology Product Name: TRx0237
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
TauRx's lead investigative oral drug, TRx0237, has been tested in 598 people with Alzheimer's. Following our 12 month blinded phase of the study, participants have moved forward to an additional one year open label phase.
Lead Product(s): Hydromethylthionine
Therapeutic Area: Neurology Product Name: TRx0237
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
This milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine topline results on the safety and efficacy of Hydromethylthionine mesylate (HMTM).
Lead Product(s): Hydromethylthionine
Therapeutic Area: Neurology Product Name: TRx0237
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
IND approval was formally given on 10 March 2022 paving the way for TauRx to build on its global strategy to bring to market the first disease modifying treatment for Alzheimer’s disease targeting the tau pathology of Alzheimer’s disease (AD).
Lead Product(s): TRx-237-801
Therapeutic Area: Neurology Product Name: TRx-237-801
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Details:
Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease.
Lead Product(s): Hydromethylthionine
Therapeutic Area: Neurology Product Name: TRx0237
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
